US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Planche V(1)(2), Villain N(3)(4).

Author information:
(1)University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
(2)Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de
Bordeaux, Bordeaux, France.
(3)AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology,
Institute of Memory and Alzheimer’s Disease, Paris, France.
(4)Institut du Cerveau – ICM, Sorbonne Université, INSERM U1127, CNRS 7225,
Paris, France.

 

Auteurs Bordeaux Neurocampus